BOLA2B: A Potential Drug Target and Biomarker (G654483)

Target Name: BOLA2B

NCBI ID: G654483

BOLA2B

BOLA2B: A Potential Drug Target and Biomarker

BOLA2B (BolA-like protein 2-like) is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BOLA2B is a 21-kDa protein that is expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues. It is characterized by a unique N-terminal region that contains a conserved catalytic core and a variable C-terminal region that is unique among proteins of its kind.

Disease-Related Characteristics

BOLA2B has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, BOLA2B has been shown to be involved in cell signaling pathways, including the TGF-β pathway, which is a well-established pathway for cancer growth and progression. BOLA2B has also been shown to play a role in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by regulating the activity of TrkB, a protein that is involved in neurotransmitter release and neurotransmission. In addition, BOLA2B has been shown to be involved in autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis, by regulating the activity of immune cells.

Potential Drug Target

The potential drug target for BOLA2B is based on its involvement in various diseases and its unique characterization. BOLA2B has been shown to be involved in several signaling pathways, including the TGF-β pathway, which is involved in cell signaling, and the PI3K/AKT signaling pathway, which is involved in cell survival and angiogenesis. Therefore, potential drugs that target these pathways may be effective in treating diseases associated with BOLA2B.

One potential drug that targets the TGF-β pathway is the drugiresistin, which is a small molecule that inhibits the activity of the TGF-β receptor. The use ofiresistin has been shown to be effective in treating cancer, including breast cancer and colorectal cancer. In addition,iresistin has also been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential drug that targets the PI3K/AKT signaling pathway is the drug perindopril, which is a peptidylated protein inhibitor of the AKT. The use ofperindopril has been shown to be effective in treating autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis. In addition,perindopril has also been shown to be effective in treating hypertension and heart failure.

Biomarker

BOLA2B has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The use ofBOLA2B as a biomarker has been shown to be effective in identifying individuals at risk of developing certain diseases, as well as tracking the effectiveness of treatments.

For example, the use ofBOLA2B as a biomarker for cancer has been shown to be effective in identifying individuals who are at risk of developing breast or ovarian cancer. Studies have shown that individuals with higher BOLA2B levels are more likely to develop these types of cancer. In addition, the use ofBOLA2B as a biomarker for neurodegenerative diseases has been shown to be effective in identifying individuals at risk of developing Alzheimer's disease and Parkinson's disease.

Conclusion

BOLA2B is a protein that has been identified as a potential drug target and biomarker in various diseases. Its unique characterization, including a conserved catalytic core and a variable C-terminal region, makes it an attractive target for small molecules and antibodies. The potential drug targets for BOLA2B, including the TGF-β pathway and the PI3K/AKT signaling pathway, as well as its potential as a biomarker, make it an

Protein Name: BolA Family Member 2B

Functions: Acts as a cytosolic iron-sulfur (Fe-S) cluster assembly factor that facilitates [2Fe-2S] cluster insertion into a subset of cytosolic proteins (PubMed:26613676, PubMed:27519415). Acts together with the monothiol glutaredoxin GLRX3 (PubMed:26613676, PubMed:27519415)

The "BOLA2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BOLA2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets